Traffic lights for ruxolitinib
- PMID: 28860323
- DOI: 10.1182/blood-2017-07-795880
Traffic lights for ruxolitinib
Conflict of interest statement
Conflict-of-interest disclosure: A.M.V. received honoraria from Novartis for participating in advisory boards and giving lectures. P.G. declares no competing financial interests.
Comment on
-
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.Blood. 2017 Aug 31;130(9):1125-1131. doi: 10.1182/blood-2017-05-783225. Epub 2017 Jul 3. Blood. 2017. PMID: 28674026 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources